Cocrystal Pharma (COCP) Stock News, Apr-Sep 2025

Cocrystal Pharma (Nasdaq: COCP) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CFO and co-CEO James Martin will deliver a company overview presentation on September 9, 2025 at 12:00 p.m. Eastern time.

The event will be held at the Lotte New York Palace Hotel, offering both in-person and virtual attendance options. Martin will be available for one-on-one meetings with institutional investors and industry professionals throughout the conference. The presentation materials are accessible on the company's website.

Cocrystal Pharma (Nasdaq: COCP) reported Q2 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988 showed favorable Phase 1 safety and tolerability results for norovirus treatment. A Phase 1b norovirus challenge study is planned for later in 2025.

Financial highlights include Q2 2025 net loss of $2.1 million ($0.20 per share), reduced from $5.3 million in Q2 2024. R&D expenses decreased to $1.1 million from $4.3 million year-over-year. The company reported $4.8 million in cash as of June 30, 2025.

CDI-988 demonstrated broad-spectrum activity against norovirus strains, including the prevalent GII.17 strains responsible for 2024-2025 outbreaks. The company's pipeline also includes CC-42344 for influenza treatment, which showed activity against highly pathogenic H5N1 avian influenza strains.

Cocrystal Pharma (Nasdaq: COCP) presented favorable Phase 1 results for its oral pan-viral inhibitor CDI-988 at the 2025 Military Health System Research Symposium. The study demonstrated that all doses (100 mg to 1200 mg) were well-tolerated, with lower treatment-emergent adverse events in CDI-988 subjects compared to placebo groups.

Key findings include: 28% adverse events in SAD cohorts (vs. 40% placebo) and 53% in MAD cohorts (vs. 92% placebo). No severe adverse events or significant ECG changes were reported. The company plans to initiate a Phase 1b challenge study with CDI-988 in norovirus-infected subjects later this year, addressing an unmet medical need as there are currently no approved treatments or vaccines for norovirus.

Cocrystal Pharma (Nasdaq: COCP) announced that its first-in-class pan-viral protease inhibitor CDI-988 has been selected for oral presentation at the 9th International Calicivirus Conference in September 2025. The presentation will showcase Phase 1 study results of CDI-988, designed as a treatment for norovirus infections.

CDI-988 was developed using Cocrystal's proprietary structure-based platform technology as a broad-spectrum inhibitor targeting 3CL viral proteases. The company has completed a Phase 1 randomized, double-blind, placebo-controlled study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The drug aims to address norovirus infections, which cause severe gastrointestinal illness with an estimated global societal cost of $60 billion annually.

Cocrystal Pharma (NASDAQ: COCP) announced that its broad-spectrum protease inhibitor CDI-988 will be presented at the 2025 Military Health System Research Symposium. The company's President and co-CEO, Sam Lee, will present Phase 1 results of CDI-988, which is being developed as a norovirus prophylaxis and treatment. CDI-988 is designed as a broad-spectrum inhibitor targeting 3CL viral proteases, showing potential for both norovirus and coronavirus treatment. The drug represents a potential breakthrough as there are currently no approved antiviral agents or vaccines for norovirus, which poses significant challenges in military settings. The company has completed a Phase 1 study evaluating safety, tolerability, and pharmacokinetics in healthy adults. The development utilizes Cocrystal's proprietary structure-based platform technology, which enables rapid development of antiviral therapies through detailed structural analysis and automated processes.

Cocrystal Pharma (NASDAQ: COCP) reports that its investigational drug CC-42344 shows exceptional potency against the 2024 H5N1 avian influenza strain. The drug demonstrated 1,000-fold higher potency compared to Tamiflu, with an EC50 of 0.003 µM versus 2.69 µM for Tamiflu. CC-42344 works by binding to the PB2 protein's conserved active site to inhibit viral replication. This development is particularly significant as the H5N1 virus has recently spread among U.S. dairy cattle, with some human cases reported, raising concerns about potential human-to-human transmission. The CDC's studies indicate extremely low to no population immunity to H5N1 viruses in the U.S., even among those vaccinated for seasonal flu. The company aims to address the multibillion-dollar influenza market, noting that approximately 8% of the U.S. population contracts influenza seasonally, resulting in $11.2 billion in annual direct and indirect costs.

Cocrystal Pharma (NASDAQ: COCP) has announced its participation in the Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference. The company's management will engage in a fireside chat on Thursday, June 5, 2025, at 12:00 p.m. Eastern time.

The event will feature a live Q&A session, and qualified investors can request one-on-one meetings with management through the conference platform. A video webcast of the presentation will be available within 48 hours on both the Cocrystal website and Channelchek, where it will remain accessible for 90 days.

Cocrystal Pharma (NASDAQ: COCP) reported Q1 2025 financial results and provided updates on its antiviral drug development programs. The company's lead candidate CDI-988, an oral pan-viral protease inhibitor, demonstrated superior broad-spectrum activity against major norovirus variants, including prevalent GII.17 and GII.4 strains. The company plans to initiate a U.S. human challenge study for CDI-988 in the coming months. Financial highlights include: Net loss of $2.3 million ($0.23 per share) compared to $4.0 million in Q1 2024, R&D expenses of $1.4 million (down from $3.0 million), and cash position of $6.9 million as of March 31, 2025. The company's pipeline includes programs targeting influenza, norovirus, and coronavirus, with CDI-988 showing potential as a dual treatment for both norovirus and coronavirus infections. The company's CC-42344 influenza program reported favorable Phase 1 results and is currently in Phase 2a trials, though experiencing delays due to low infection rates among study participants.

Cocrystal Pharma (NASDAQ: COCP) announces significant progress with its norovirus oral antiviral candidate CDI-988, which has demonstrated potent activity against emerging GII.17 variants that have become the dominant strain in 2024-2025 U.S. and European outbreaks. The drug candidate shows broad-spectrum antiviral activity against both GII.4 and GII.17 strains.

CDI-988, a pan-viral protease inhibitor, has completed Phase 1 trials with favorable safety and tolerability results. The company plans to initiate a human challenge study in 2025 for both treatment and prevention of norovirus infection. The drug targets the highly conserved region of the GII.17 protease, representing a potential first-in-class oral antiviral treatment.

Notably, norovirus causes approximately 685 million cases and 50,000 child deaths annually worldwide, with an estimated societal cost of $60 billion. Currently, there are no approved antiviral treatments or vaccines available.